Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05478304
Other study ID # CP-2021-05
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 25, 2023
Est. completion date April 2032

Study information

Verified date May 2024
Source AtriCure, Inc.
Contact Kirstin Smentek
Phone 612.430.1398
Email ksmentek@atricure.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.


Recruitment information / eligibility

Status Recruiting
Enrollment 6500
Est. completion date April 2032
Est. primary completion date December 2031
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects = 18 years of age - Documentation of any of the following clinical criteria: - CHA2DS2-VASc = 4 with age = 65 - CHA2DS2-VASc = 4 with significant left atrium enlargement or elevated NT-proBNP - CHA2DS2-VASc = 3 with age = 75 - CHA2DS2-VASc = 3 with significant left atrium enlargement or elevated NT-proBNP - CHA2DS2-VASc score = 2 with age = 65 and significant left atrium enlargement or elevated NT-proBNP Exclusion Criteria: - Clinically significant atrial fibrillation or atrial flutter: - Anytime in the past and - Documented by an electrocardiographic recording and - Episode lasting 6 minutes or longer1* - Prior procedure involving opening the pericardium or entering the pericardial space - Prior LAA occlusion, exclusion, or removal (surgical or percutaneous) - Planned cardiac surgical procedure using non-sternotomy approaches o Partial sternotomies will be allowed. - Patients whose planned procedure is a heart transplant or implantation of any ventricular assist devices - Active endocarditis - Active systemic infection at the time of cardiac surgery requiring antibiotics, including known SARS-CoV2 infections regardless of symptoms - Known allergy to Nitinol or nickel sensitivity - Known medical condition with expected survival of less than 1 year - Other comorbidities that in the investigator's opinion make the subject unsuitable candidate to complete the protocol required visits. - Current enrollment in an investigation or trial or an investigational devices or investigational drug that would interfere with this trial. - Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the trial. - Pregnancy - Known severe symptomatic carotid disease

Study Design


Related Conditions & MeSH terms


Intervention

Device:
AtriClip LAA Exclusion System
LAAE using the AtriClip concomitant to and at the time of planned cardiac surgery

Locations

Country Name City State
Canada Hamilton General Hospital Hamilton Ontario
Canada Montreal Heart Institute Montréal Quebec
Canada IUCPQ / Hospital Laval Québec
Canada New Brunswick Heart Centre Saint John New Brunswick
Canada St Michael's Hospital Toronto Ontario
United Kingdom Northern General Hospital Sheffield Great Britain
United States Lehigh Valley Health Network Allentown Pennsylvania
United States University of Michigan Ann Arbor Michigan
United States Emory University Hospital Atlanta Georgia
United States Piedmont Hospital Atlanta Georgia
United States UT Dell Medical School Austin Texas
United States Johns Hopkins Hospital Baltimore Maryland
United States Massachusetts General Hospital Boston Massachusetts
United States Ascension St. Vincent Carmel Indiana
United States Medical University of South Carolina (MUSC) Charleston South Carolina
United States Northwestern Memorial Hospital Chicago Illinois
United States Christ Hospital / Lindner Research Center Cincinnati Ohio
United States TriHealth / Bethesda North Hospital Cincinnati Ohio
United States University Hospitals of Cleveland Cleveland Ohio
United States Ohio State Medical Center Columbus Ohio
United States Riverside Methodist Columbus Ohio
United States Mercy Medical Center Des Moines Iowa
United States Inova Fairfax Medical Falls Church Virginia
United States HealthPark Medical Center Fort Myers Florida
United States University of Florida Hospital Gainesville Florida
United States Corewell Health Grand Rapids Michigan
United States Hackensack University Medical Center Hackensack New Jersey
United States UPMC Pinnacle Harrisburg Pennsylvania
United States Hartford Hospital Hartford Connecticut
United States Heart Center Research / Huntsville Hospital Huntsville Alabama
United States Portneuf Medical Center Idaho Falls Idaho
United States Franciscan Indianapolis Indiana
United States Jackson Madison County General Jackson Tennessee
United States St. Bernard's Heart & Vascular Jonesboro Arkansas
United States Midwest Heart and Vascular (HCA) Kansas City Missouri
United States St. Luke's Hospital Kansas City Kansas
United States Lancaster General Hospital Lancaster Pennsylvania
United States University of Kentucky Lexington Kentucky
United States Arkansas Heart Hospital Little Rock Arkansas
United States CHI St. Vincent Little Rock Arkansas
United States Memorial Care Long Beach Medical Center Long Beach California
United States Keck Medical Center of USC Los Angeles California
United States University of Louisville Health / Jewish Hospital Louisville Kentucky
United States North Shore University Hospital (Northwell) Manhasset New York
United States Wellstar - Kennestone Marietta Georgia
United States Loyola University Medical Center Maywood Illinois
United States Baptist Health South Florida Miami Florida
United States Columbia St. Mary's Milwaukee Wisconsin
United States Abbott Northwestern / Minneapolis Heart Minneapolis Minnesota
United States West Virginia University Morgantown West Virginia
United States Ascension St. Thomas West Nashville Tennessee
United States Centennial Medical Center (TriStar) Nashville Tennessee
United States Hoag Memorial Hospital Presbyterian Newport Beach California
United States Sentara Hospitals & Sentara Medical Group Norfolk Virginia
United States Nebraska Methodist Omaha Nebraska
United States The Nebraska Medical Center Omaha Nebraska
United States Orlando Regional Medical Center Orlando Florida
United States Allegheny General Hospital Pittsburgh Pennsylvania
United States UPMC Health System Pittsburgh Pennsylvania
United States Baylor Heart Hospital - Plano Plano Texas
United States WakeMed Health & Hospitals Raleigh North Carolina
United States Mayo Clinic Rochester Minnesota
United States St. Francis Hospital Roslyn New York
United States St. Lukes Hospital Saint Louis Missouri
United States Washington University Saint Louis Missouri
United States University of Utah Salt Lake City Utah
United States Sarasota Memorial Hospital Sarasota Florida
United States HonorHealth Shea Scottsdale Healthcare Scottsdale Arizona
United States Swedish Heart and Vascular Research Seattle Washington
United States Memorial Hospital (SIU Medicine) Springfield Illinois
United States St. Joseph Hospital Syracuse New York
United States Baycare Health System Tampa Florida
United States The Toledo Hospital (Promedica) Toledo Ohio
United States North Mississippi Medical Center Tupelo Mississippi
United States Trinity Mother Frances (CHRISTUS) Tyler Texas
United States Medstar Washington Hospital Center Washington District of Columbia
United States Aspirus Hospital Wausau Wisconsin
United States Novant Presbyterian Hospital Winston-Salem North Carolina
United States Wake Forest Baptist Winston-Salem North Carolina
United States Lankenau Hospital Wynnewood Pennsylvania
United States Trinity Health (formerly St. Joesph Mercy) Ypsilanti Michigan

Sponsors (2)

Lead Sponsor Collaborator
AtriCure, Inc. Population Health Research Institute

Countries where clinical trial is conducted

United States,  Canada,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Effectiveness Endpoint Time to the first occurrence of ischemic stroke or systemic arterial embolism as adjudicated by the Clinical Events Committee (CEC), or any procedure wherein the LAA was excluded, occluded, or amputated following the index procedure. Common termination point (median follow-up for 5 years)
Primary Primary Safety Endpoint Occurrence of at least one of the following events assessed through 30 days post index procedure:
Pericardial effusion requiring percutaneous or surgical treatment
Major bleeding attributable to index surgical procedure
Deep sternal wound infection
Myocardial infarction
30 days post index procedure
Secondary Powered Secondary Effectiveness endpoint Time to the first occurrence of ischemic stroke or systemic arterial embolism Common termination point (median follow-up for 5 years)
See also
  Status Clinical Trial Phase
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05518305 - Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
Recruiting NCT06029959 - Stroke and CPAP Outcome Study 3 N/A
Recruiting NCT03728738 - Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke Phase 3
Terminated NCT03396419 - IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
Recruiting NCT05065216 - Treatment of Acute Ischemic Stroke (ReMEDy2 Trial) Phase 2/Phase 3
Recruiting NCT04897334 - Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke N/A
Not yet recruiting NCT06462599 - Osteopontin Gene Polymorphism in Stroke Patients in Egypt
Not yet recruiting NCT06032819 - Differentiating Between Brain Hemorrhage and Contrast
Not yet recruiting NCT06026696 - Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
Recruiting NCT02910180 - Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Completed NCT03554642 - Walkbot Robotic Training for Improvement in Gait Phase 3
Completed NCT02922452 - A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects Phase 1
Withdrawn NCT01866189 - Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke N/A
Recruiting NCT03041753 - Reperfusion Injury After Stroke Study N/A
Completed NCT02549846 - AdminiStration of Statin On Acute Ischemic stRoke patienT Trial Phase 4
Completed NCT01678534 - Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial Phase 2
Completed NCT02610803 - Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke N/A